MAPT and Alzheimer disease: In Alzheimer's disease (AD), complement activation associated with inflammation and glial cell activation has long been recognized but considered secondary to amyloid‐β (Aβ)‐ and tau‐mediated pathology (Musiek & Holtzman, 2015).